← Back to Search

InheRET for Cancer-Predisposing Syndrome

N/A
Waitlist Available
Led By David Keren, MD
Research Sponsored by InheRET, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up follow up surveys 12- to 18-months following completion of the inheret program.
Awards & highlights

Study Summary

This study is evaluating whether a tool that helps people gather family history information can help people get the right kind of cancer screening.

Eligible Conditions
  • Cancer-Predisposing Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~follow up surveys 12- to 18-months following completion of the inheret program.
This trial's timeline: 3 weeks for screening, Varies for treatment, and follow up surveys 12- to 18-months following completion of the inheret program. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pre- and Post-Rate of Referrals of Patients to Genetic Counseling from Primary Care Clinics
Secondary outcome measures
Patient Acceptance of InheRET
Physician Acceptance and Impact
Qualitative Impact on Patients

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Post-InheRETExperimental Treatment3 Interventions
Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
Group II: Pre-InheRETActive Control1 Intervention
Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.

Find a Location

Who is running the clinical trial?

University of MichiganOTHER
1,794 Previous Clinical Trials
6,371,684 Total Patients Enrolled
InheRET, IncLead Sponsor
David Keren, MDPrincipal InvestigatorInheRET, Inc

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease
2020. "Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04510896.
All > Hereditary Angioedema
~487 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top